Vaccines - Poland

Poland

In Poland, the revenue in the Vaccines market is forecasted to reach US$485.40m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of -4.83%, leading to a market volume of US$378.90m by 2029.
When compared globally, United States is anticipated to generate the highest revenue, amounting to US$29,120.00m in 2024.
Poland has rapidly increased its vaccine production capacity to meet the growing demand for immunization.

Key regions: Australia, Italy, France, South Korea, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for vaccines in Poland has been on the rise in recent years due to several factors.

Customer preferences: Polish consumers have become increasingly health-conscious and are more willing to invest in preventative measures such as vaccines. Additionally, the COVID-19 pandemic has heightened awareness of the importance of vaccines and has led to an increase in demand for all types of vaccines.

Trends in the market: One of the main trends in the Polish vaccines market is the growing popularity of private vaccination clinics. These clinics offer a wider range of vaccines than public healthcare institutions and often have shorter waiting times. Another trend is the increasing demand for vaccines among adults, particularly for travel-related vaccines.

Local special circumstances: Poland has a large population of older adults, which has contributed to the high demand for vaccines such as the flu vaccine. Additionally, the country has a large agricultural sector, which has led to a demand for vaccines for livestock.

Underlying macroeconomic factors: Poland has a growing economy and an increasing middle class, which has led to higher healthcare spending and a greater willingness to invest in preventative healthcare measures such as vaccines. The country also has a well-established pharmaceutical industry, which has helped to support the development and distribution of vaccines.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.